Nemanja Z. Petrovic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nemanja Z. Petrovic has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Slobodan M. Jankovic
Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia
3 shared publications - Ana V. Pejcic
Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
2 shared publications - Miloš Milosavljević
Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
2 shared publications - Aleksandar Rančić
Inst Publ Hlth Kragujevac, Kragujevac, Serbia
1 shared publication - Aleksandra Petrovic Kitic
Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia
1 shared publication - Ana Barjaktarević
Department of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia
1 shared publication
Latest Publications
- Open Access
- 23 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (15) , 5756
Results of Endovascular Treatment of Ruptured Intracranial Aneurysms and Recanalization Rate After a Five-Year Follow-Up Period
Background/Objectives: Endovascular embolization of ruptured intracranial arterial aneurysms has become the first-choice treatment due to its minimal invasiveness, rapid patient recovery, and lower complication rate. The aim of this study was to analyze putative risk factors of unfavorable outcomes of ruptured intracranial aneurysms after coil embolization and the recanalization rate. Methods: This case series included adult patients with ruptured intracranial aneurysms who underwent endovascular embolization during the study period of 2007–2023. In total, 1080 patients with ruptured intracranial aneurysms treated using endovascular coiling participated in this study. Results: During the first year after the initial intervention, repeated embolization was performed for 50 patients (5.5%). Treatment outcome was assessed using the modified Rankin Scale, and neuroradiological follow-up was conducted during a five-year period on 672 patients. During the period from one to five years, re-embolization was performed in 11 (1.5%) cases, of which only three occurred during the last 3 years of follow-up. Conclusions: Endovascular embolization is a safe method for the treatment of ruptured intracranial aneurysms, with a low complication rate and good clinical outcome. Higher risk for repeated aneurysm embolization is associated with male sex, alcohol consumption, smoking, hyperlipidemia, aneurysm size, diabetes, aneurysm location, and obliteration rate. This study showed that aneurysms in which recanalization is not observed within 2 years after coil embolization remain stable during a follow-up period of 5 years, except in the case of large aneurysms and low obliteration rates.
- 23 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (15) , 5756
Open AccessResults of Endovascular Treatment of Ruptured Intracranial Aneurysms and Recanalization Rate After a Five-Year Follow-Up Period
Background/Objectives: Endovascular embolization of ruptured intracranial arterial aneurysms has become the first-choice treatment due to its minimal invasiveness, rapid patient recovery, and lower complication rate. The aim of this study was to analyze putative risk factors of unfavorable outcomes of ruptured intracranial aneurysms after coil embolization and the recanalization rate. Methods: This case series included adult patients with ruptured intracranial aneurysms who underwent endovascular embolization during the study period of 2007–2023. In total, 1080 patients with ruptured intracranial aneurysms treated using endovascular coiling participated in this study. Results: During the first year after the initial intervention, repeated embolization was performed for 50 patients (5.5%). Treatment outcome was assessed using the modified Rankin Scale, and neuroradiological follow-up was conducted during a five-year period on 672 patients. During the period from one to five years, re-embolization was performed in 11 (1.5%) cases, of which only three occurred during the last 3 years of follow-up. Conclusions: Endovascular embolization is a safe method for the treatment of ruptured intracranial aneurysms, with a low complication rate and good clinical outcome. Higher risk for repeated aneurysm embolization is associated with male sex, alcohol consumption, smoking, hyperlipidemia, aneurysm size, diabetes, aneurysm location, and obliteration rate. This study showed that aneurysms in which recanalization is not observed within 2 years after coil embolization remain stable during a follow-up period of 5 years, except in the case of large aneurysms and low obliteration rates.
- Open Access
- 1 June 2026
- Published by Walter de Gruyter GmbH in Experimental and Applied Biomedical Research (EABR)
- Vol. 27 (2) , 179-186
Predictors of Adverse Drug Reactions to Reserve Antibiotics in Hospitalized Patients: A Tertiary Care Study
Reserve antibiotics are frequently used in hospitalized patients with severe infections, particularly in tertiary healthcare institutions. Although these agents are essential for the treatment of multidrug-resistant infections, their use may be associated with an increased risk of adverse drug reactions(ADRs). Identification of clinical and laboratory predictors of ADRs may contribute to safer and more rational antibiotic therapy. To determine the frequency of ADRs during treatment with reserve antibiotics in hospitalized patients at the University Clinical Center Kragujevac (UCCKg) and to identify factors associated with their occurrence. This observational study had a prospective–retrospective design and included spontaneous reporting of ADRs to reserve antibiotics by clinical pharmacologists during regular consultations with patients receiving these drugs. The study was conducted in all units of the UCCKg among patients for whom a consultation with a clinical pharmacologist had been requested by the attending physician between January 2022 and December 2023. Data were collected from the consultation registry archive and the electronic health information system of the UCCKg. Among patients receiving reserve antibiotics who were consulted by clinical pharmacologist, 52 developed ADRs. Significant factors associated with their occurrence were chronic renal insufficiency(adjusted OR 3.36), heart failure(adjusted OR 0.26), and peptic ulcer disease(adjusted OR 0.27). Reserve antibiotics are essential in the treatment of severe infections and are frequently used in tertiary healthcare institutions. Their use is associated with a certain incidence of ADRs, particularly in patients with renal failure or prolonged severe infections. These factors should be considered during treatment planning to prevent unfavorable outcomes.
- 1 June 2026
- Published by Walter de Gruyter GmbH in Experimental and Applied Biomedical Research (EABR)
- Vol. 27 (2) , 179-186
Open AccessPredictors of Adverse Drug Reactions to Reserve Antibiotics in Hospitalized Patients: A Tertiary Care Study
Reserve antibiotics are frequently used in hospitalized patients with severe infections, particularly in tertiary healthcare institutions. Although these agents are essential for the treatment of multidrug-resistant infections, their use may be associated with an increased risk of adverse drug reactions(ADRs). Identification of clinical and laboratory predictors of ADRs may contribute to safer and more rational antibiotic therapy. To determine the frequency of ADRs during treatment with reserve antibiotics in hospitalized patients at the University Clinical Center Kragujevac (UCCKg) and to identify factors associated with their occurrence. This observational study had a prospective–retrospective design and included spontaneous reporting of ADRs to reserve antibiotics by clinical pharmacologists during regular consultations with patients receiving these drugs. The study was conducted in all units of the UCCKg among patients for whom a consultation with a clinical pharmacologist had been requested by the attending physician between January 2022 and December 2023. Data were collected from the consultation registry archive and the electronic health information system of the UCCKg. Among patients receiving reserve antibiotics who were consulted by clinical pharmacologist, 52 developed ADRs. Significant factors associated with their occurrence were chronic renal insufficiency(adjusted OR 3.36), heart failure(adjusted OR 0.26), and peptic ulcer disease(adjusted OR 0.27). Reserve antibiotics are essential in the treatment of severe infections and are frequently used in tertiary healthcare institutions. Their use is associated with a certain incidence of ADRs, particularly in patients with renal failure or prolonged severe infections. These factors should be considered during treatment planning to prevent unfavorable outcomes.
- Open Access
- 23 May 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (6) , 777
Safety Profile of Antipsychotics as Predictors of the Quality of Life in Patients with Schizophrenia—An Inpatient Welfare Institution-Based Cross-Sectional Study
Background/Objectives: Adverse effects of antipsychotics represent a significant limiting factor in achieving favorable therapeutic outcomes in the treatment of schizophrenia, and may contribute to a diminished quality of life among affected individuals. The primary objective of this study was to identify and evaluate the adverse effects of antipsychotics in patients diagnosed with schizophrenia who were treated at the social welfare institution, as well as to analyze the impact of these adverse effects on patients’ overall quality of life. Methods: A clinical, observational cross-sectional study was conducted, involving a sample of 278 patients diagnosed with schizophrenia. The patients were assessed in terms of their sociodemographic and clinical characteristics. Adverse effects of antipsychotics were evaluated using The Udvalg for Kliniske Undersøgelser (UKU) Side Effect Rating Scale, while quality of life was assessed in the previous study. Results: The average number of adverse effects per patient with schizophrenia was 3.56 for psychiatric, 1.18 for neurological, 2.62 for autonomic, and 7.12 for other side effects. The average UKU score was 17.22 ± 11.04, with significant differences based on accommodation, antipsychotic type, and dosing regimen. UKU scores were negatively correlated with the EuroQoL 5-Dimension 5-Level (EQ-5D-5L) index, Visual Analog Scale (VAS) score, the Quality-of-Life Enjoyment and Satisfaction Questionnaire—Short Form (Q-LES-Q-SF) score, and the scores of physical and psychological domains of the World Health Organization Quality-of-Life Scale (WHOQOL-BREF). Conclusions: The findings of this study suggest that the presence of antipsychotic-related adverse effects is a significant determinant that can negatively influence the quality of life in patients with schizophrenia. These results underscore the importance of an individualized approach when determining pharmacological treatment strategies in the management of schizophrenia.
- 23 May 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (6) , 777
Open AccessSafety Profile of Antipsychotics as Predictors of the Quality of Life in Patients with Schizophrenia—An Inpatient Welfare Institution-Based Cross-Sectional Study
Background/Objectives: Adverse effects of antipsychotics represent a significant limiting factor in achieving favorable therapeutic outcomes in the treatment of schizophrenia, and may contribute to a diminished quality of life among affected individuals. The primary objective of this study was to identify and evaluate the adverse effects of antipsychotics in patients diagnosed with schizophrenia who were treated at the social welfare institution, as well as to analyze the impact of these adverse effects on patients’ overall quality of life. Methods: A clinical, observational cross-sectional study was conducted, involving a sample of 278 patients diagnosed with schizophrenia. The patients were assessed in terms of their sociodemographic and clinical characteristics. Adverse effects of antipsychotics were evaluated using The Udvalg for Kliniske Undersøgelser (UKU) Side Effect Rating Scale, while quality of life was assessed in the previous study. Results: The average number of adverse effects per patient with schizophrenia was 3.56 for psychiatric, 1.18 for neurological, 2.62 for autonomic, and 7.12 for other side effects. The average UKU score was 17.22 ± 11.04, with significant differences based on accommodation, antipsychotic type, and dosing regimen. UKU scores were negatively correlated with the EuroQoL 5-Dimension 5-Level (EQ-5D-5L) index, Visual Analog Scale (VAS) score, the Quality-of-Life Enjoyment and Satisfaction Questionnaire—Short Form (Q-LES-Q-SF) score, and the scores of physical and psychological domains of the World Health Organization Quality-of-Life Scale (WHOQOL-BREF). Conclusions: The findings of this study suggest that the presence of antipsychotic-related adverse effects is a significant determinant that can negatively influence the quality of life in patients with schizophrenia. These results underscore the importance of an individualized approach when determining pharmacological treatment strategies in the management of schizophrenia.
- Open Access
- 5 July 2024
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 41 (4) , 248-260
Vitamin C Levels in Pregnant Women and the Efficacy of Vitamin C Supplements in Preventing Premature Rupture of Membranes: A Systematic Review and Meta-Analysis
Premature rupture of membranes (PROM) is defined as the leakage of amniotic fluid before the onset of labor and delivery contractions. Some studies found that women who experienced PROM had significantly lower vitamin C blood levels than those who did not, while others found no significant differences. Previous systematic reviews and meta-analyses on the efficacy of vitamin C in the prevention of PROM had conflicting results. We aimed to conduct a systematic review and meta-analysis to determine if there was a significant difference in vitamin C blood levels in women who had PROM versus the control group who did not and to determine if vitamin C supplements could help prevent it. Systematic review and meta-analysis. We registered our protocol with PROSPERO (CRD42022371644). We searched PubMed/MEDLINE, Web of Science, and Scopus through February 15, 2024. Additionally, backward and forward citation searches were conducted. Studies were selected based on predetermined inclusion and exclusion criteria. Meta-Essentials: Workbooks for Meta-Analysis (Version 1.5) was used for analysis. Twenty-five studies (26 reports) met all eligibility criteria, with 18 studies (18 reports) assessing vitamin C levels and seven studies (eight reports) evaluating efficacy. Women with PROM, whether preterm or term, had significantly lower vitamin C levels [Hedges' g, -1.48; 95% confidence interval (CI): -2.82, -0.14; p = 0.020; I2 = 94.08%) and specifically preterm PROM after removing the outlying study [Hedges' g, -1.29; 95% CI: -1.85, -0.73; p < 0.001; I2 = 87.35%). Vitamin C supplementation significantly reduced the risk of preterm or term PROM [risk ratio (RR), 0.57; 95% CI: 0.39, 0.81; p < 0.001; I2 = 12.17%), particularly for preterm PROM (RR, 0.67; 95% CI: 0.45, 0.99; p = 0.001; I2 = 0.00%). There were no significant differences in vitamin C levels between women with term PROM and controls, and there were no differences in the risk of developing term PROM between women taking vitamin C supplements and controls. Results were not robust in all sensitivity analyses. Women with PROM, particularly those who developed it preterm, appear to have significantly lower vitamin C levels, and vitamin C supplementation appears to be effective in reducing the risk of PROM, particularly preterm PROM. More high-quality studies with low risk of bias, more homogenous, and larger samples are needed to confirm these findings.
- 5 July 2024
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 41 (4) , 248-260
Open AccessVitamin C Levels in Pregnant Women and the Efficacy of Vitamin C Supplements in Preventing Premature Rupture of Membranes: A Systematic Review and Meta-Analysis
Premature rupture of membranes (PROM) is defined as the leakage of amniotic fluid before the onset of labor and delivery contractions. Some studies found that women who experienced PROM had significantly lower vitamin C blood levels than those who did not, while others found no significant differences. Previous systematic reviews and meta-analyses on the efficacy of vitamin C in the prevention of PROM had conflicting results. We aimed to conduct a systematic review and meta-analysis to determine if there was a significant difference in vitamin C blood levels in women who had PROM versus the control group who did not and to determine if vitamin C supplements could help prevent it. Systematic review and meta-analysis. We registered our protocol with PROSPERO (CRD42022371644). We searched PubMed/MEDLINE, Web of Science, and Scopus through February 15, 2024. Additionally, backward and forward citation searches were conducted. Studies were selected based on predetermined inclusion and exclusion criteria. Meta-Essentials: Workbooks for Meta-Analysis (Version 1.5) was used for analysis. Twenty-five studies (26 reports) met all eligibility criteria, with 18 studies (18 reports) assessing vitamin C levels and seven studies (eight reports) evaluating efficacy. Women with PROM, whether preterm or term, had significantly lower vitamin C levels [Hedges' g, -1.48; 95% confidence interval (CI): -2.82, -0.14; p = 0.020; I2 = 94.08%) and specifically preterm PROM after removing the outlying study [Hedges' g, -1.29; 95% CI: -1.85, -0.73; p < 0.001; I2 = 87.35%). Vitamin C supplementation significantly reduced the risk of preterm or term PROM [risk ratio (RR), 0.57; 95% CI: 0.39, 0.81; p < 0.001; I2 = 12.17%), particularly for preterm PROM (RR, 0.67; 95% CI: 0.45, 0.99; p = 0.001; I2 = 0.00%). There were no significant differences in vitamin C levels between women with term PROM and controls, and there were no differences in the risk of developing term PROM between women taking vitamin C supplements and controls. Results were not robust in all sensitivity analyses. Women with PROM, particularly those who developed it preterm, appear to have significantly lower vitamin C levels, and vitamin C supplementation appears to be effective in reducing the risk of PROM, particularly preterm PROM. More high-quality studies with low risk of bias, more homogenous, and larger samples are needed to confirm these findings.
- Open Access
- 9 April 2024
- Published by Polish Pharmaceutical Society in Acta Poloniae Pharmaceutica - Drug Research
- Vol. 81 (1) , 71-82
Validation of Novel High-Performance Liquid Chromatography Method for Meropenem Quantification in Plasma
- 9 April 2024
- Published by Polish Pharmaceutical Society in Acta Poloniae Pharmaceutica - Drug Research
- Vol. 81 (1) , 71-82
Open AccessValidation of Novel High-Performance Liquid Chromatography Method for Meropenem Quantification in Plasma
- Open Access
- 1 January 2024
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Galenika Medical Journal
- Vol. 3 (9) , 6-12
Population pharmacokinetics of vancomycin in hemodialysis patients
Introduction: Vancomycin is a glycopeptide antibiotic, which is primarily effective against Gram-positive aerobic and most Gram-positive anaerobic bacteria. It is known that the pharmacokinetics of vancomycin are significantly altered in hemodialysis patients, which may result in reduced efficacy or increased toxicity of the drug. Objective: The objective of this paper was to investigate the influence of several potential factors on the elimination of vancomycin in hemodialysis patients. Method: A retrospective observational study of case series type was conducted. The study includes hospitalized patients with terminal chronic renal failure who are on intermittent hemodialysis at the University Clinical Center Kragujevac (UKC KG) and who developed an infection with Gram-positive bacteria. Development of a one-compartment population pharmacokinetic (PPK) model without absorption for vancomycin was performed using the NONMEM software package. Results: A total of 60 critically ill patients on hemodialysis were included in this study. Estimated vancomycin clearance and volume of distribution values in the base model were 1.16 L/h and 324 L, respectively. The full PPK model of vancomycin had 5 significant covariates: daily dose of vancomycin, weekly number of hemodialysis sessions, duration of each dialysis session, co-administration of levofloxacin, and co-administration of fluconazole. It was shown that only 1 out of 5 individual covariates from the full model met the necessary statistical requirements, and that was the daily dose of vancomycin. Conclusion: Vancomycin clearance in hemodialysis patients depends on various factors, including dialysis efficiency and patient characteristics. Clinicians must carefully monitor vancomycin levels in hemodialysis patients, adjusting doses as needed to ensure therapeutic efficacy while minimizing the risk of toxicity.
- 1 January 2024
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Galenika Medical Journal
- Vol. 3 (9) , 6-12
Open AccessPopulation pharmacokinetics of vancomycin in hemodialysis patients
Introduction: Vancomycin is a glycopeptide antibiotic, which is primarily effective against Gram-positive aerobic and most Gram-positive anaerobic bacteria. It is known that the pharmacokinetics of vancomycin are significantly altered in hemodialysis patients, which may result in reduced efficacy or increased toxicity of the drug. Objective: The objective of this paper was to investigate the influence of several potential factors on the elimination of vancomycin in hemodialysis patients. Method: A retrospective observational study of case series type was conducted. The study includes hospitalized patients with terminal chronic renal failure who are on intermittent hemodialysis at the University Clinical Center Kragujevac (UKC KG) and who developed an infection with Gram-positive bacteria. Development of a one-compartment population pharmacokinetic (PPK) model without absorption for vancomycin was performed using the NONMEM software package. Results: A total of 60 critically ill patients on hemodialysis were included in this study. Estimated vancomycin clearance and volume of distribution values in the base model were 1.16 L/h and 324 L, respectively. The full PPK model of vancomycin had 5 significant covariates: daily dose of vancomycin, weekly number of hemodialysis sessions, duration of each dialysis session, co-administration of levofloxacin, and co-administration of fluconazole. It was shown that only 1 out of 5 individual covariates from the full model met the necessary statistical requirements, and that was the daily dose of vancomycin. Conclusion: Vancomycin clearance in hemodialysis patients depends on various factors, including dialysis efficiency and patient characteristics. Clinicians must carefully monitor vancomycin levels in hemodialysis patients, adjusting doses as needed to ensure therapeutic efficacy while minimizing the risk of toxicity.
- 11 December 2023
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 23 (1) , 67-78
Priapism associated with anti-seizure medications: a pharmacovigilance study and a review of published cases
BackgroundRecently, case reports of priapism associated with the use of some anti-seizure medications began to emerge in the literature. We aimed to investigate if there is a potential safety signal of priapism among individual anti-seizure medications and to search the literature for relevant published cases.Research design and methodsWe conducted a disproportionality analysis using OpenVigil 2.1 to query the United States Food and Drug Administration's Adverse Event Reporting System (FAERS) database. Literature search was conducted in PubMed/MEDLINE, Scopus and Web of Science up to 12 July 2023.ResultsWe identified positive signal of priapism for valproic acid and its derivatives (n = 23, chi-squared = 59.943, PRR = 4.566), gabapentin (n = 20, chi-squared = 9.790, PRR = 2.060), lamotrigine (n = 16, chi-squared = 8.318, PRR = 2.120), levetiracetam (n = 16, chi-squared = 10.766, PRR = 2.329), topiramate (n = 14, chi-squared = 28.067, PRR = 3.972) and carbamazepine (n = 8, chi-squared = 6.147, PRR = 2.568), as well as published cases of priapism associated with these drugs. We also found published cases of priapism for pregabalin and phenytoin in the literature and FAERS, and at least one reported adverse event of priapism in FAERS for clonazepam, lacosamide, ethosuximide, oxcarbazepine, and vigabatrin in which they were considered primary suspect.ConclusionsOur study identified signals for priapism for several anti-seizure medications, but these results need to be confirmed in well-designed pharmacoepidemiological studies.
- 11 December 2023
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 23 (1) , 67-78
Priapism associated with anti-seizure medications: a pharmacovigilance study and a review of published cases
BackgroundRecently, case reports of priapism associated with the use of some anti-seizure medications began to emerge in the literature. We aimed to investigate if there is a potential safety signal of priapism among individual anti-seizure medications and to search the literature for relevant published cases.Research design and methodsWe conducted a disproportionality analysis using OpenVigil 2.1 to query the United States Food and Drug Administration's Adverse Event Reporting System (FAERS) database. Literature search was conducted in PubMed/MEDLINE, Scopus and Web of Science up to 12 July 2023.ResultsWe identified positive signal of priapism for valproic acid and its derivatives (n = 23, chi-squared = 59.943, PRR = 4.566), gabapentin (n = 20, chi-squared = 9.790, PRR = 2.060), lamotrigine (n = 16, chi-squared = 8.318, PRR = 2.120), levetiracetam (n = 16, chi-squared = 10.766, PRR = 2.329), topiramate (n = 14, chi-squared = 28.067, PRR = 3.972) and carbamazepine (n = 8, chi-squared = 6.147, PRR = 2.568), as well as published cases of priapism associated with these drugs. We also found published cases of priapism for pregabalin and phenytoin in the literature and FAERS, and at least one reported adverse event of priapism in FAERS for clonazepam, lacosamide, ethosuximide, oxcarbazepine, and vigabatrin in which they were considered primary suspect.ConclusionsOur study identified signals for priapism for several anti-seizure medications, but these results need to be confirmed in well-designed pharmacoepidemiological studies.